Summit Therapeutics PLC saw a significant boost in its stock price following a major investment from AstraZeneca.
Summit Therapeutics PLC (NASDAQ:SMMT) experienced a notable increase in its stock price yesterday, rising by 3.70% to close at CA$17.95. This surge was primarily driven by AstraZeneca's recent announcement of a $2 billion equity investment in Summit, aimed at accelerating the development of its investigational drug, ivonescimab.
Advertisement
Summit Therapeutics PLC
SMMT.US
SMMT.US
Summit Therapeutics PLC
WealthAwesomeMarket cap
$12.42B
52W high
$29.23
52W low
$12.07
1W change
+3.67%
Beta
-1.52
Analyst Price Targets
Based on 17 analysts covering SMMT · as of Oct 21, 2026
Wall Street analysts forecast SMMT stock price to rise 87.8% over the next 12 months.
Consensus
Buy4.24 / 5.00
Avg. Target
C$30.22
+87.8% Upside
Previously C$30.20 on Oct 19, 2026
Current Price
C$16.09
Last close
Analyst Breakdown (17 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on SMMT's historical volatility
30-Day Vol
61.3%
Annualized
90-Day Vol
66.0%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$18.92
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$16.80 | C$13.60 – C$20.76 |
| 60 trading days | C$17.83 | C$13.22 – C$24.05 |
| 90 trading days | C$18.92 | C$13.12 – C$27.30 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: The collaboration with AstraZeneca not only provides substantial funding but also enhances Summit's potential in the oncology space, making it a stock to watch for investors interested in biotech.
SMMT's stock rose by 3.70%
This increase reflects investor optimism following AstraZeneca's $2 billion investment and collaboration for ivonescimab's development.
Bull case
The partnership with AstraZeneca could lead to major advancements in cancer treatment, positioning Summit as a leader in oncology. With this financial backing, Summit can speed up clinical trials and explore new applications for ivonescimab, creating significant market opportunities.
Bear case
However, investors should remain cautious, as the biotech sector carries inherent risks. The success of ivonescimab isn't guaranteed, and regulatory challenges could slow progress. Delays or failures in clinical trials could negatively affect Summit's stock price.
Advertisement
AstraZeneca's Strategic Investment
AstraZeneca's $2 billion commitment to Summit Therapeutics shows strong confidence in ivonescimab, a bispecific antibody targeting cancer. This investment will help expand clinical trials and explore new treatment combinations, especially for solid tumors like breast and lung cancers.
Potential Impact on Summit's Growth
The collaboration with AstraZeneca is expected to boost Summit's development capabilities, allowing for quicker progress in clinical trials. With ivonescimab showing promise across various cancer types, this partnership may open new revenue streams and enhance Summit's market presence, making it an attractive option for biotech investors.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
